Human RCTHumanRandomizedBlindedControlled
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Takara L. Stanley, Meghan N. Feldpausch, Jinhee Oh, Karen L. Branch, Hang Lee, Martin Torriani, Steven K. Grinspoon
Study design
Methods snapshot
- Population
- Antiretroviral-treated adults with HIV and abdominal fat accumulation
- Sample size
- 50
- Intervention
- Tesamorelin
- Route
- Subcutaneous
- Dose reported
- 2 mg
- Frequency
- Daily
- Duration
- 6 months
- Control / placebo
- Controlled study
Outcomes
Primary
- Visceral adipose tissue
- Liver fat
Secondary
- Glucose and other metabolic endpoints
Results
The trial reported reductions in visceral adipose tissue and liver fat versus placebo over six months.
Interpretation
The findings apply to the studied population and protocol; they should not be generalized to unstudied indications or populations.
Adverse events
Not indexed in the current record.
Limitations
- Single-center study
- Disease-specific population
- 48 participants received study treatment
Connected records
Original source
Sempre consulte o artigo original para métodos completos, análises e contexto editorial.
Open PubMed record ↗